5-tert-butyl 2-ethyl 6,6-dimethyl-3-{[4-(trifluoromethyl)benzoyl]amino}pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate | 1041015-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-tert-butyl 2-ethyl 6,6-dimethyl-3-{[4-(trifluoromethyl)benzoyl]amino}pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate
• 英文别名: 5-O-tert-butyl 2-O-ethyl 6,6-dimethyl-3-[[4-(trifluoromethyl)benzoyl]amino]-4H-pyrrolo[3,4-c]pyrazole-2,5-dicarboxylate
• CAS: 1041015-55-7
• 化学式: C₂₃H₂₇F₃N₄O₅
• 分子量: 496.486
• InChiKey: WKCUVGWHZAXTEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5-tert-butyl 2-ethyl 6,6-dimethyl-3-{[4-(trifluoromethyl)benzoyl]amino}pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 生成 ethyl 6,6-dimethyl-3-{[4-(trifluoromethyl)benzoyl]amino}-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate hydrochloride
  参考文献：
  名称：

  Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing

  摘要：

  We have recently reported CDK inhibitors based on the 6-substituted pyrrolo[3,4-c]pyrazole core structure. Improvement of inhibitory potency against multiple CDKs, antiproliferative activity against cancer cell lines and optimization of the physico-chemical properties led to the identification of highly potent compounds. Compound 31 (PHA-793887) showed good efficacy in the human ovarian A2780, colon HCT-116 and pancreatic BX-PC3 carcinoma xenograft models and was well tolerated upon daily treatments by iv administration. It was identified as a drug candidate for clinical evaluation in patients with solid tumors.

  DOI：

  10.1016/j.bmc.2010.01.042
• 作为产物：
  描述：

  3-氨基-6,6-二甲基- 吡咯并[3,4-c]吡唑-2,5(4H,6H)-二羧酸 5-(1,1-二甲基乙基) 2-乙酯 、 4-三氟甲基苯甲酰氯 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 5-tert-butyl 2-ethyl 6,6-dimethyl-3-{[4-(trifluoromethyl)benzoyl]amino}pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate
  参考文献：
  名称：

  Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing

  摘要：

  We have recently reported CDK inhibitors based on the 6-substituted pyrrolo[3,4-c]pyrazole core structure. Improvement of inhibitory potency against multiple CDKs, antiproliferative activity against cancer cell lines and optimization of the physico-chemical properties led to the identification of highly potent compounds. Compound 31 (PHA-793887) showed good efficacy in the human ovarian A2780, colon HCT-116 and pancreatic BX-PC3 carcinoma xenograft models and was well tolerated upon daily treatments by iv administration. It was identified as a drug candidate for clinical evaluation in patients with solid tumors.

  DOI：

  10.1016/j.bmc.2010.01.042

文献信息

• CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS
  申请人：Zhang Junhu

  公开号：US20090318440A1

  公开（公告）日：2009-12-24

  Carbonylamino Pyrrolopyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.

  提供了化学式I的羰基氨基吡咯吡唑化合物，包括这些化合物的组合物以及它们的使用方法。化学式I的优选化合物具有作为蛋白激酶抑制剂的活性，包括作为PAK4的抑制剂。
• US7884117B2
  申请人：——

  公开号：US7884117B2

  公开（公告）日：2011-02-08
• Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing
  作者：Maria Gabriella Brasca、Clara Albanese、Rachele Alzani、Raffaella Amici、Nilla Avanzi、Dario Ballinari、James Bischoff、Daniela Borghi、Elena Casale、Valter Croci、Francesco Fiorentini、Antonella Isacchi、Ciro Mercurio、Marcella Nesi、Paolo Orsini、Wilma Pastori、Enrico Pesenti、Paolo Pevarello、Patrick Roussel、Mario Varasi、Daniele Volpi、Anna Vulpetti、Marina Ciomei

  DOI：10.1016/j.bmc.2010.01.042

  日期：2010.3

  We have recently reported CDK inhibitors based on the 6-substituted pyrrolo[3,4-c]pyrazole core structure. Improvement of inhibitory potency against multiple CDKs, antiproliferative activity against cancer cell lines and optimization of the physico-chemical properties led to the identification of highly potent compounds. Compound 31 (PHA-793887) showed good efficacy in the human ovarian A2780, colon HCT-116 and pancreatic BX-PC3 carcinoma xenograft models and was well tolerated upon daily treatments by iv administration. It was identified as a drug candidate for clinical evaluation in patients with solid tumors.